Ravi Paluri

Dr. Ravi Paluri

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2019 in Oncology Reviews
Verified
Journal Article
Open access
PDF file
SHSyed Hasan
Syed Hasan
RJRojymon Jacob
Rojymon Jacob
UMUpender Manne
Upender Manne
RPRavi Paluri
Ravi Paluri
Biomarkers play an essential role in the management of patients with invasive cancers. Pancreatic ductal adenocarcinoma (PDC) associated with poor prognosis due to advanced presentation and limited therapeutic options. This is further complicated by absence of validated screening and predictive biomarkers for early diagnosis and precision treatments respectively. There is emerging data on biomarkers in pancreatic cancer in past two decades. So far, the CA 19-9 remains the only approved biomarker for diagnosis and response assessment but limited by low sensitivity and specificity. In this article, we aim to review current and future biomarkers that has potential serve as critical tools for early diagnostic, predictive and prognostic indications in pancreatic cancer.

30 October 2020 in JCO Oncology Practice
Verified
Journal Article
Closed access
SGSmith Giri
Smith Giri
DCDeanna Clark
Deanna Clark
MAMustafa Al-Obaidi
Mustafa Al-Obaidi
WVWill Varnado
Will Varnado
SKSeema Kumar
Seema Kumar
GWGrant Williams
Grant Williams
PURPOSE: Financial distress (FD) among older adults with cancer is not well studied. We sought to characterize prevalence and factors associated with FD among older adults with cancer and the association of FD with geriatric assessment (GA) –identified deficits. PATIENTS AND METHODS: We included adults age ≥ 60 years with cancer in the University of Alabama at Birmingham Cancer and Aging Resilience Evaluation Registry who underwent GA during initial consultation with a medical oncologist before starting systemic therapy. We captured FD using a single-item question: “Do you have to pay for more medical care than you can afford?” We built multivariable models to study the impact of sociodemographic/clinical factors on FD as well as the association of FD with GA impairments. RESULTS: We identified 447 older adults with a median age of 69 years; 60% were men, 75% were White, and colorectal (26%) and pancreatic (19%) cancers were the most common. Overall, 27% (n = 121) reported having FD. Factors associated with FD included being Black (v White; odds ratio [OR], 2.26; 95% CI, 1.35 to 3.81; P = .002), being disabled/unemployed (v employed; OR, 2.60; 95% CI, 1.17 to 5.76; P = .019), and having an advanced degree ( v less than high school; OR, 0.13; 95% CI, 0.03 to 0.65; P = .012). Patients with FD were more likely to report several GA impairments, including depression (OR, 2.10; 95% CI, 1.06 to 4.18; P = .034) and impaired health-related quality of life in physical (β = −2.82; P = .014) and mental health domains (β = −3.31; P = .002). CONCLUSION: More than a quarter of older adults with cancer reported FD at the time of initial presentation to an oncologist. Several demographic factors and GA impairments were associated with FD.

23 July 2020 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
MAMuhammad Yasir Anwar
Muhammad Yasir Anwar
GWGrant R. Williams
Grant R. Williams
RPRavi Paluri
Ravi Paluri

25 June 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
AJAllan M. Johansen
Allan M. Johansen
Steven ForsytheSteven Forsythe
Steven Forsythe
CMCallum T. McGrath
Callum T. McGrath
GBGrayson Barker
Grayson Barker
HJHugo Jimenez
Hugo Jimenez
BPBoris C. Pasche
Boris C. Pasche
TGFβ is a pleiotropic signaling pathway that plays a pivotal role in regulating a multitude of cellular functions. TGFβ has a dual role in cell regulation where it induces growth inhibition and cell death; however, it can switch to a growth-promoting state under cancerous conditions. TGFβ is upregulated in colorectal cancer and pancreatic cancer, altering the tumor microenvironment and immune system and promoting a mesenchymal state. The upregulation of TGFβ in certain cancers leads to resistance to immunotherapy, and attempts to inhibit TGFβ expression have led to reduced therapeutic resistance when combined with chemotherapy and immunotherapy. Here, we review the current TGFβ inhibitor drugs in clinical trials for pancreatic and colorectal cancer, with the goal of uncovering advances in improving clinical efficacy for TGFβ combinational treatments in patients. Furthermore, we discuss the relevance of alterations in TGFβ signaling and germline variants in the context of personalizing treatment for patients who show lack of response to current therapeutics.

22 July 2019 in Oncology Reviews
Verified
Journal Article
Open access
PDF file
RPRavi Paluri
Ravi Paluri
GSGuru P. Sonpavde
Guru P. Sonpavde
CMCharity Morgan
Charity Morgan
JRJacob Rojymon
Jacob Rojymon
AMAnastasia Hartzes Mar
Anastasia Hartzes Mar
RGRadhika Gangaraju
Radhika Gangaraju
A meta-analysis of randomized clinical trials (RCT) was done to determine the relative risk (RR) of acute kidney injury (AKI) with the use of mammalian target of rapamycin (mTOR) inhibitors. Citations from PubMed/Medline, clinical trials.gov, package inserts and abstracts from major conferences were reviewed to include RCTs comparing arms with or without mTOR inhibitors. The RR of all grade AKI in patients taking mTOR inhibitors compared to patients not on mTOR inhibitors was 1.55 (95% CI: 1.11 to 2.16, P=0.010). There was no significant difference in the risk of high-grade AKI for the two groups (RR=1.29, P=0.118, 95% CI: 0.94 to 1.77). There was no significant difference in the incidence rates for either all grade or high-grade AKI between the two groups. There was no publication bias and the trials were of high quality per Jadad scoring.

25 September 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TMTimothy McGinnis
Timothy McGinnis
LBLeonidas E. Bantis
Leonidas E. Bantis
RMRashna Madan
Rashna Madan
Prasad DandawatePrasad Dandawate
Prasad Dandawate
SKSean Kumer
Sean Kumer
AKAnup Kasi
Anup Kasi
Pancreatic intraepithelial neoplasms (PanINs) and intraductal papillary mucinous neoplasms (IPMNs) are common pancreatic adenocarcinoma precursor lesions. However, data regarding their respective associations with survival rate and prognosis are lacking. We retrospectively evaluated 72 pancreatic adenocarcinoma tumor resection patients at the University of Kansas Hospital between August 2009 and March 2019. Patients were divided into one of two groups, PanIN or IPMN, based on the results of the surgical pathology report. We compared baseline characteristics, overall survival (OS), and progression free survival (PFS) between the two groups, as well as OS and PFS based on local or distant tumor recurrence for both groups combined. 52 patients had PanINs and 20 patients had IPMNs. Patients who had an IPMN precursor lesion had better median PFS and OS when compared to patients with PanIN precursor lesions. However, the location of tumor recurrence (local or distant) did not show a statistically significant difference in OS.